Details of the Drug
General Information of Drug (ID: DM0EBWR)
| Drug Name |
5-{8(Z),11(Z)-pentadecadienyl}resorcinol
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
5-{8(Z),11(Z)-pentadecadienyl}resorcinol; CHEMBL459604; 5-(8,11-Pentadecadienyl)-1,3-benzenediol; 5-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,3-diol; Cardoldiene; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)benzene-1,3-diol; SCHEMBL9475761; DTXSID70872872; MolPort-005-944-663; 79473-25-9; ZINC31157863; LMPK15030021; BDBM50292428; AKOS030555484; MCULE-2398296746; RESORCINOL(15:2(8Z,11Z)); 5-(pentadeca-8,11-dienyl)benzene-1,3-diol; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)resorcinol
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 316.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 7.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 12 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


